Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free JANX Stock Alerts

Janux Therapeutics (JANX) Competitors

Janux Therapeutics logo
$14.33 -0.09 (-0.62%)
Closing price 04:00 PM Eastern
Extended Trading
$14.60 +0.27 (+1.87%)
As of 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

JANX vs. OGN, VKTX, EWTX, NAMS, and RCUS

Should you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Organon & Co. (OGN), Viking Therapeutics (VKTX), Edgewise Therapeutics (EWTX), NewAmsterdam Pharma (NAMS), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does Janux Therapeutics compare to Organon & Co.?

Janux Therapeutics (NASDAQ:JANX) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Organon & Co. has a net margin of 3.99% compared to Janux Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 103.27% beat Janux Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -12.61% -12.08%
Organon & Co. 3.99%103.27%6.19%

In the previous week, Organon & Co. had 13 more articles in the media than Janux Therapeutics. MarketBeat recorded 18 mentions for Organon & Co. and 5 mentions for Janux Therapeutics. Organon & Co.'s average media sentiment score of 0.33 beat Janux Therapeutics' score of -0.03 indicating that Organon & Co. is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Organon & Co.
4 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Janux Therapeutics presently has a consensus target price of $49.75, suggesting a potential upside of 247.17%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 14.51%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Janux Therapeutics is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.60
Organon & Co.
3 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.57

Janux Therapeutics has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 29.4% of Janux Therapeutics shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$10M87.36-$113.62M-$1.83N/A
Organon & Co.$6.22B0.56$187M$0.9314.34

Summary

Organon & Co. beats Janux Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Janux Therapeutics compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Janux Therapeutics has higher revenue and earnings than Viking Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$359.64M-$4.14N/A
Janux Therapeutics$10M87.36-$113.62M-$1.83N/A

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Janux Therapeutics' return on equity of -12.61% beat Viking Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -71.31% -65.35%
Janux Therapeutics N/A -12.61%-12.08%

In the previous week, Viking Therapeutics had 27 more articles in the media than Janux Therapeutics. MarketBeat recorded 32 mentions for Viking Therapeutics and 5 mentions for Janux Therapeutics. Viking Therapeutics' average media sentiment score of 0.24 beat Janux Therapeutics' score of -0.03 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viking Therapeutics
6 Very Positive mention(s)
6 Positive mention(s)
8 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral
Janux Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Viking Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.58, suggesting that its share price is 158% more volatile than the S&P 500.

Viking Therapeutics presently has a consensus target price of $95.50, suggesting a potential upside of 205.01%. Janux Therapeutics has a consensus target price of $49.75, suggesting a potential upside of 247.17%. Given Janux Therapeutics' higher possible upside, analysts plainly believe Janux Therapeutics is more favorable than Viking Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
2.85
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.60

Summary

Janux Therapeutics beats Viking Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Janux Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/A-$167.79M-$1.63N/A
Janux Therapeutics$10M87.36-$113.62M-$1.83N/A

75.4% of Janux Therapeutics shares are owned by institutional investors. 23.2% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 29.4% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Janux Therapeutics' return on equity of -12.61% beat Edgewise Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Edgewise TherapeuticsN/A -31.97% -30.46%
Janux Therapeutics N/A -12.61%-12.08%

In the previous week, Edgewise Therapeutics had 5 more articles in the media than Janux Therapeutics. MarketBeat recorded 10 mentions for Edgewise Therapeutics and 5 mentions for Janux Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.69 beat Janux Therapeutics' score of -0.03 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edgewise Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Janux Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Edgewise Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500.

Edgewise Therapeutics currently has a consensus target price of $38.13, suggesting a potential upside of 0.30%. Janux Therapeutics has a consensus target price of $49.75, suggesting a potential upside of 247.17%. Given Janux Therapeutics' higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Edgewise Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edgewise Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.89
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.60

Summary

Janux Therapeutics beats Edgewise Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to NewAmsterdam Pharma?

Janux Therapeutics (NASDAQ:JANX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Janux Therapeutics has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$10M87.36-$113.62M-$1.83N/A
NewAmsterdam Pharma$22.50M152.69-$203.82M-$1.73N/A

Janux Therapeutics currently has a consensus target price of $49.75, suggesting a potential upside of 247.17%. NewAmsterdam Pharma has a consensus target price of $48.00, suggesting a potential upside of 60.64%. Given Janux Therapeutics' higher possible upside, equities analysts plainly believe Janux Therapeutics is more favorable than NewAmsterdam Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.60
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

Janux Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -906.22%. Janux Therapeutics' return on equity of -12.61% beat NewAmsterdam Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -12.61% -12.08%
NewAmsterdam Pharma -906.22%-26.67%-24.82%

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 29.4% of Janux Therapeutics shares are owned by insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Janux Therapeutics and Janux Therapeutics both had 5 articles in the media. NewAmsterdam Pharma's average media sentiment score of 0.83 beat Janux Therapeutics' score of -0.03 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
NewAmsterdam Pharma
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Janux Therapeutics has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500.

Summary

Janux Therapeutics beats NewAmsterdam Pharma on 8 of the 14 factors compared between the two stocks.

How does Janux Therapeutics compare to Arcus Biosciences?

Janux Therapeutics (NASDAQ:JANX) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 29.4% of Janux Therapeutics shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Janux Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$10M87.36-$113.62M-$1.83N/A
Arcus Biosciences$247M13.27-$353M-$3.30N/A

Janux Therapeutics currently has a consensus target price of $49.75, suggesting a potential upside of 247.17%. Arcus Biosciences has a consensus target price of $32.44, suggesting a potential upside of 24.38%. Given Janux Therapeutics' higher probable upside, research analysts clearly believe Janux Therapeutics is more favorable than Arcus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.60
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64

Janux Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -142.91%. Janux Therapeutics' return on equity of -12.61% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -12.61% -12.08%
Arcus Biosciences -142.91%-65.77%-32.51%

Janux Therapeutics has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

In the previous week, Arcus Biosciences had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Arcus Biosciences and 5 mentions for Janux Therapeutics. Arcus Biosciences' average media sentiment score of 0.00 beat Janux Therapeutics' score of -0.03 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcus Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Janux Therapeutics beats Arcus Biosciences on 11 of the 16 factors compared between the two stocks.

Get Janux Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JANX vs. The Competition

Export
MetricJanux TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$873.56M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-7.8338.8529.0428.47
Price / Sales87.36155.53476.6160.94
Price / CashN/A57.8827.6236.52
Price / Book0.907.039.676.67
Net Income-$113.62M$23.62M$3.55B$332.53M
7 Day Performance-1.17%3.67%1.70%2.01%
1 Month Performance-3.44%7.16%5.62%9.20%
1 Year Performance-51.90%67.03%34.42%39.59%

Janux Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JANX
Janux Therapeutics
3.1313 of 5 stars		$14.33
-0.6%		$49.75
+247.2%		N/A$873.56M$10MN/A30
OGN
Organon & Co.
2.5853 of 5 stars		$13.27
-0.2%		$11.40
-14.1%		N/A$3.49B$6.22B14.2610,000
VKTX
Viking Therapeutics
3.6405 of 5 stars		$31.76
+5.9%		$95.50
+200.7%		N/A$3.48BN/AN/A20
EWTX
Edgewise Therapeutics
1.0462 of 5 stars		$31.45
+2.7%		$38.13
+21.2%		N/A$3.29BN/AN/A60
NAMS
NewAmsterdam Pharma
3.9157 of 5 stars		$29.86
+5.0%		$48.00
+60.8%		N/A$3.27B$22.50MN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:JANX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel